15 articles
Bortezomib and dexamethasone regimen
The bortezomib–dexamethasone (Vd) regimen is a two-drug treatment for multiple myeloma that combines bortezomib with dexamethasone, approved for relapsed disease after at least one prior therapy.
Bortezomib and lenalidomide combination regimen
The bortezomib and lenalidomide combination regimen, known as VRd, is a three-drug chemotherapy regimen for multiple myeloma that pairs a proteasome inhibitor with an immunomodulatory drug and dexamethasone.
Carfilzomib/lenalidomide regimen
The carfilzomib/lenalidomide regimen, usually written KRd, is a triplet of carfilzomib, lenalidomide, and dexamethasone for multiple myeloma, FDA-approved for relapsed or refractory disease after one to three prior therapies.
Cedazuridine
Cedazuridine (E7727, ASTX727, Inqovi) is an oral cytidine deaminase inhibitor paired with decitabine; FDA approved 2020 for MDS/CMML and, from 2026, AML with venetoclax, giving IV-equivalent decitabine exposure.
Cyclophosphamide/dexamethasone regimen
The cyclophosphamide/dexamethasone (Cy-Dex) regimen is a chemotherapy combination pairing the alkylating agent cyclophosphamide with the corticosteroid dexamethasone, formerly used as induction therapy for multiple myeloma before stem cell transplantation.
Daratumumab regimen
A daratumumab regimen is a multiple myeloma treatment combining the CD38 antibody daratumumab with backbone drugs such as dexamethasone, bortezomib, or lenalidomide, across newly diagnosed and relapsed disease.
Golcadomide
Golcadomide (CC-99282, BMS-986369) is an investigational oral Bristol Myers Squibb cereblon E3 ligase modulator (CELMoD) that degrades Ikaros and Aiolos; unapproved, in phase 1-3 lymphoma trials including GOLSEEK-1.
Iberdomide
Iberdomide, sold as Zenbexus, is an oral cereblon E3 ligase modulator developed by Bristol Myers Squibb and approved in 2026 for relapsed or refractory multiple myeloma.
Ixazomib
Ixazomib (Ninlaro) is the first oral proteasome inhibitor, approved in 2016 with lenalidomide and dexamethasone for relapsed multiple myeloma after one prior therapy; TOURMALINE-MM1 improved PFS but not overall survival.
Lenalidomide/low-dose dexamethasone regimen
The lenalidomide/low-dose dexamethasone regimen (Rd) is an oral, chemotherapy-free doublet for multiple myeloma, pairing lenalidomide with once-weekly dexamethasone, established as standard first-line therapy by the FIRST trial.
Melphalan flufenamide
Melphalan flufenamide (melflufen; Pepaxto/Pepaxti) is an alkylating peptide-drug conjugate by Oncopeptides for relapsed/refractory multiple myeloma; FDA-approved 2021, withdrawn 2024, EU-authorized as Pepaxti since 2022.
Mezigdomide
Mezigdomide (CC-92480, BMS-986348) is an oral cereblon E3 ligase modulator (CELMoD) degrading Ikaros/Aiolos, investigated for relapsed/refractory multiple myeloma; SUCCESSOR-2 showed PFS 18.0 vs 8.3 months, FDA NDA accepted 2026.
Pomalidomide
Pomalidomide (Pomalyst, Imnovid, CC-4047) is an oral thalidomide-analogue IMiD for relapsed/refractory multiple myeloma with dexamethasone; FDA accelerated approval 2013, cereblon mechanism, REMS-restricted.
Pomalidomide and dexamethasone regimen
The pomalidomide–dexamethasone regimen (Pd) is an all-oral combination treatment for relapsed and refractory multiple myeloma, approved in 2013 and used as the doublet backbone for pomalidomide-based triplets.
Selinexor
Selinexor (XPOVIO, Nexpovio) is an oral first-in-class XPO1 nuclear export inhibitor (SINE) approved since 2019 for multiple myeloma and relapsed/refractory DLBCL, with thrombocytopenia, nausea, and hyponatremia as key toxicities.